Opportunities
Search

Buyer: Waterford and Wexford Education and Training Board_110494 | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2027-12-17

Buyer: Lysekils kommun | Notice type: cn-standard | Procedure: restricted | Contract: services | Deadline: 2027-12-17

Buyer: Etelä-Pohjanmaan hyvinvointialue | Notice type: cn-standard | Procedure: restricted | Contract: supplies | Deadline: 2027-12-17

Buyer: Coöperatie Samen Innoveren/Inkopen/Ict voor Onderwijs Nederland UA | Notice type: cn-standard | Procedure: restricted | Contract: services | Deadline: 2027-12-19

Buyer: Специализирана болница за активно лечение по детски болести – проф.Иван Митев ЕАД | Notice type: cn-standard | Procedure: restricted | Contract: supplies | Deadline: 2027-12-20

Buyer: Многопрофилна болница за активно лечение "Проф. д-р Александър Герчев" Етрополе ЕООД | Notice type: cn-standard | Procedure: restricted | Contract: supplies | Deadline: 2027-12-20

Buyer: УНИВЕРСИТЕТСКА МНОГОПРОФИЛНА БОЛНИЦА ЗА АКТИВНО ЛЕЧЕНИЕ - Д-Р ГЕОРГИ СТРАНСКИ ЕАД | Notice type: cn-standard | Procedure: restricted | Contract: supplies | Deadline: 2027-12-23

Buyer: LITGRID, AB | Notice type: cn-standard | Procedure: oth-single | Contract: works | Deadline: 2027-12-23

The goal of the NHLBI Catalyze Program is to provide a comprehensive suite of support and services to facilitate the transition of basic science discoveries into viable diagnostic and therapeutic candidates that have been cleared for human testing, and to develop translational researchers fluent in product development and entrepreneurship. This specific Catalyze Product Definition initiative will provide the early stage translational support needed for the activities required to identify and characterize potential therapeutic candidates and combination products to treat HLBS diseases and disorders. This initiative has a companion initiative that supports development of devices and diagnostics and is also part of a suite of innovation grants to advance projects to the point where they can meet the entry criteria for the NHLBI Catalyze Preclinical Program.

The goal of the NHLBI Catalyze Program is to provide a comprehensive suite of support and services to facilitate the transition of basic science discoveries into viable diagnostic and therapeutic candidates that have been cleared for human testing, and to develop translational researchers fluent in product development and entrepreneurship. This specific Catalyze Product Definition initiative will provide the early stage translational supportneeded for the activities required to identify and characterize potential therapeutic candidates and combination products to treat HLBS diseases and disorders. This initiative has a companion initiative that supports development of devices and diagnostics and is also part of a suite of innovation grants to advance projects to the point where they can meet the entry criteria for the NHLBI Catalyze Preclinical Program.

The goal of the NHLBI Catalyze Program is to provide a comprehensive suite of support and services to facilitate the transition of basic science discoveries into viable diagnostic and therapeutic candidates that have been cleared for human testing, and to develop translational researchers fluent in product development and entrepreneurship. This specific Catalyze Enabling Technologies and Transformative Platforms initiative will support needed to rigorously validate transformative, multi-use platforms or technologies that can enable. Well-suited applications must offer the potential to significantly accelerate and/or transform the areas of early detection and screening, model development, clinical diagnosis, treatment, control, behavior, prevention or epidemiology. Proposed platforms and technologies may have widespread applicability but must be able to improve the outlook for HLBS-related diseases and disorders.

The goal of the NHLBI Catalyze Program is to provide a comprehensive suite of support and services to facilitate the transition of basic science discoveries into viable diagnostic and therapeutic candidates that have been cleared for human testing, and to develop translational researchers fluent in product development and entrepreneurship. This specific Catalyze Product Definition initiative will provide the early stage translational support needed for prototype testing/design modification, assay development for diagnostic disease targets, and development of research tools for use in the treatment of HLBS diseases and disorders. Following successful completion of the program, it is expected that the potential products will be poised to move forward for in vivo testing (optimization, safety, efficacy) with additional support from NIH and/or other federal and private programs. This initiative has a companion initiative that supports development of therapeutics and combination products and is also part of a suite of innovation grants to advance projects to the point where they can meet the entry criteria for the NHLBI Catalyze Preclinical Program.

The goal of the NHLBI Catalyze Program is to provide a comprehensive suite of support and services to facilitate the transition of basic science discoveries into viable diagnostic and therapeutic candidates that have been cleared for human testing, and to develop translational researchers fluent in product development and entrepreneurship. This specific Catalyze Product Definition initiative will provide the early stage translational support needed for the activities required to develop and test device prototypes, identify diagnostic disease targets and develop associated assays, and develop research tools to treat HLBS diseases and disorders. This is a phased initiative for early stage projects. The R61 phase provides support to identify and test initial prototype designs, to identify a disease target and generate experimental design, and to identify, test and pilot research tools. The R33 phase provides support for continued prototype development and testing, in addition to modifying design features and user feedback, diagnostic product generation, exploration of assay components, and characterization of a load design, and research tool improvement, large trial testing and data integration. Following successful completion of the program, it is expected that the potential products will be poised to move forward for in vivo testing (optimization, safety, efficacy) with additional support from NIH and/or other federal and private programs. This initiative has a companion initiative that supports development of therapeutics and combination products and is also part of a suite...

Buyer: AOK Niedersachsen. Die Gesundheitskasse. | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2027-12-28

Buyer: AOK Niedersachsen. Die Gesundheitskasse. | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2027-12-28

Buyer: AOK Niedersachsen. Die Gesundheitskasse. | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2027-12-28

Buyer: AOK Niedersachsen. Die Gesundheitskasse. | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2027-12-28

Buyer: AOK Niedersachsen. Die Gesundheitskasse. | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2027-12-28

Buyer: Pohjois-Pohjanmaan hyvinvointialue | Notice type: cn-social | Procedure: restricted | Contract: services | Deadline: 2027-12-30

Buyer: Elinvoimakeskus sekä työllisyys-, kehittämis- ja hallintokeskus | Notice type: cn-standard | Procedure: restricted | Contract: services | Deadline: 2027-12-30

Buyer: Jyväskylän kaupunki | Notice type: cn-social | Procedure: restricted | Contract: services | Deadline: 2027-12-30

Buyer: Uppsala kommun | Notice type: cn-standard | Procedure: open | Contract: works | Deadline: 2027-12-30

Buyer: Pohjois-Karjalan hankintatoimi | Notice type: cn-standard | Procedure: restricted | Contract: supplies | Deadline: 2027-12-30

Buyer: Pohjois-Pohjanmaan hyvinvointialue | Notice type: cn-social | Procedure: restricted | Contract: services | Deadline: 2027-12-30

Buyer: Hessen Mobil, Straßen- und Verkehrsmanagement, Zentrale | Notice type: cn-standard | Procedure: open | Contract: services | Deadline: 2027-12-30